Integrum Appoints Thomas Dugan as President, US

Report this content

Mölndal, Sweden, October 15, 2021.

Integrum AB announced today that Thomas Dugan has been appointed President of Integrum Inc., US. An experienced business leader, Mr. Dugan will lead our important US business and assume his responsibilities immediately.

Mr. Dugan is a highly experienced and successful executive with a strong track record of building businesses and delivering results leading both large and small, start-up companies. Most recently a partner with 360 Life Sciences Advisors, he was also the CEO of Amniox Medical, Inc., President of SurgiQuest, Inc., President of America’s for Smith & Nephew Wound Care.

“Tom has the perfect background to accelerate the scaling up of our business now when FDA has granted us full market access via the recent Pre-Market Approval (PMA).  We look forward to his leadership as we continue to grow the adoption in leading hospital systems of our novel bone-anchored prosthetic implant system in the US” said Rickard Brånemark, Chairman of the Board, Integrum AB.

“While we conducted an extensive search, Tom rose quickly to the top of our list, and we look forward to the impact he will have at making our important bone-anchored prosthetic implant system available to a broader range of patients in the US.”  Andy Christensen, Member of the Board, Integrum AB. 

This information is such that Integrum AB (publ) is required to publish in accordance with the EU Market Abuse Regulation and the Swedish Security Markets Act. The information was submitted for publication, through the agency by the contact persons set out below on October 15, 2021, at 2:00 pm (CET).

For further information, please contact:
Maria Lopez, CEO
Phone: +46 (0) 708 46 10 69

Dennis Baecklund, CFO
Phone: +46 (0) 725 56 68 69 

Certified Adviser:
Erik Penser Bank AB
Tel. +46 (0) 8 463 8000

About Integrum 
Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.

In December 2020, Integrum successfully completed the most stringent medical device regulatory procedure in the world, and based on the solid scientific data submitted, was granted a PMA by the FDA for the OPRA ​​Implant System, which is the only technology approved for above knee, bone-anchored prosthetics in the U.S. More information on the company and its innovative solutions for amputees can be found at


Dokument & länkar